

## UNMARKETABLE PARCEL SHARE SALE FACILITY

ITL Health Group Limited ("ITL") announces that it has established a share sale facility ("facility") for holders of unmarketable parcels of shares in ITL.

An unmarketable parcel of shares, as defined by the Australian Securities Exchange ("ASX"), is a parcel of shares that has a market value of less than \$500. Based on a 5 day volume weighted average price (VWAP) at market close on 29 November 2018 (Record Date) an unmarketable parcel of shares is any shareholding of 5,208 ordinary shares or less (Unmarketable Parcel) based on the VWAP of 0.096 cents

Currently, there are 214 holders of unmarketable parcels in ITL. ITL is providing the facility to allow investors with small holdings, and who might otherwise find it difficult to sell their shares due to the small size of the holdings, the opportunity to sell their shares without any brokerage costs.

The key dates in relation to the facility are:

<b>Record Date:</b>	29 November 2018
<b>ASX Announcement:</b>	30 November 2018
<b>Letters sent to shareholders:</b>	5 December 2018
<b>Closing Date for Share Retention Form:</b>	16 January 2019

Attached is a copy of the letter to shareholders explaining the terms and conditions.

### About ITL Health Group [www.itlhealthgroup.com](http://www.itlhealthgroup.com)

ITL is an innovative global medical technology company comprising two divisions; ITL BioMedical and MyHealthTest. ITL holds an IP portfolio of more than 50 patents and sells into 55 countries.

ITL BioMedical creates and manufactures leading edge medical devices for the global blood industry including products for the clinical, blood banking, and laboratory markets. ITL is a growing provider of specialist ancillary products for the Blood Culture Testing and Blood Stream Infection Prevention markets.

MyHealthTest is developing a disruptive business model in the pathology testing market and is building an innovative platform for driving and leveraging the direct to consumer healthcare revolution.

### ITL Health Group

ITL is an innovative global medical technology company comprising two divisions; ITL BioMedical and MyHealthTest. ITL holds an IP portfolio of more than 50 patents and sells into 55 countries.

ITL BioMedical creates and manufactures leading edge medical devices for the global blood industry including products for the clinical, blood banking, and laboratory markets. ITL is a growing provider of specialist ancillary products for the Blood Culture Testing and Blood Stream Infection Prevention markets.

MyHealthTest is developing a disruptive business model in the pathology testing market and is building an innovative platform for driving and leveraging the direct to consumer healthcare revolution.



Ranked 16<sup>th</sup> most Innovative Company by the  
AFR Innovative Companies Awards

**Australian Securities Exchange**  
Code: ITD

**Ordinary Shares**  
85,552,339

**Board of Directors**  
Bill Mobbs Executive Chairman  
Mark Peatey Non-executive Director  
Andrew Turnbull Non-executive Director

Trevor Doolan Chief Financial Officer &  
Company Secretary

**ITL Contact**  
Trevor Doolan Company Secretary  
Phone: +61 3 9088 7991  
Email: [info@itlhealthgroup.com](mailto:info@itlhealthgroup.com)  
Address: Level 3, 10 Moore Street,  
Canberra, ACT 2601

[www.itlhealthgroup.com](http://www.itlhealthgroup.com)

**Media**  
Walbrook IR Ben Knowles  
Phone: +61 426 277 760  
Email: [ben.knowles@walbrookir.co.au](mailto:ben.knowles@walbrookir.co.au)

5 December 2018

Dear Shareholder

### **Notice of Intention to Sell Unmarketable Parcel of Shares in ITL Health Group Limited**

We are writing to advise you that ITL Health Group Limited (**ITL** or **Company**) has established a share sale facility (Facility) for holders of shares in the Company (Shares) valued at less than \$500 as at 7:00pm (AEDT) on 29 November 2018 (Record Date)

The Facility has been established in accordance with the ASX Listing Rules and the Company's Constitution to assist holders of Unmarketable Parcels to sell their Shares. Under the Facility, the Company has appointed Boardroom Pty Limited to assist in transferring the shares from the shareholders name to a designated account for the shares to be sold, at no cost to the shareholder. If your Shares are held in a CHESS Holding, the Company may, without further notice, move your Shares to an Issuer Sponsored Holding or a certified holding for the purposes of selling your Shares under the Facility.

Our records indicate that you held an Unmarketable Parcel of Shares on the Record Date. Unless you advise the Company that you do NOT wish to sell your Shares by 5:00 pm on 16 January 2019, being six weeks from the date of this letter (Closing Date), ITL intends to sell your Shares through the Facility as soon as practicable thereafter. Payment will be sent to you following settlement of the sale. Subject to the prevailing market conditions, it is intended that the Shares are sold at a price of \$0.096 cents per Share, being the volume weighted average sale price of the Company's Shares on ASX during the five trading days immediately preceding the Record Date. Please note that if at the closing date your shares are worth more than \$500 then they will not be classified as an unmarketable parcel and will not be sold under this program.

### **What are your options?**

You have two options - you can either sell your Shares through the Facility or choose to retain your Shares.

#### **1) Selling your Shares**

If you wish to sell your Shares through the Facility, you do not need to take any further action. By not taking any action by the Closing Date, you acknowledge and accept that:

- a) you have irrevocably appointed the Company as your agent to sell your Unmarketable Parcel through the Facility and to deal with the proceeds of the sale of the Shares in accordance with the process outlined in this letter; and
- b) if your Shares are in a CHESS Holding as at the Closing Date, the Company may move those Shares to an Issuer Sponsored Holding or a certificated holding without further notice.

## 2) Retaining your Shares

If you do NOT wish to sell your Shares through the Facility, you will need to complete and return the attached Share Retention Form so that it is received by the Company by the Closing Date, being 5:00 pm on 16 January 2019. Please read the instructions on the Share Retention Form carefully before completing it.

## Sale Proceeds

Subject to the Corporations Act 2001 (Cth), the Company will bear all costs, including brokerage and stamp duty, associated with the sale of any Shares under the Facility. The Company will pay you the sale proceeds following settlement of all Shares through the Facility. Where direct credit details have not been provided by you, you will receive a cheque for the sale proceeds.

## Summary of Key Dates

Please note the below proposed key dates in relation to the sale of Unmarketable Parcels under the Facility:

Unmarketable Parcels Record Date 7:00pm (AEST) on 29 November 2018

Unmarketable Parcels Facility Announcement to ASX 30 November 2018

Letters sent to shareholders holding Unmarketable Parcels 5 December 2018

Closing Date for receipt of Share Retention Form 16 January 2019

Estimated Unmarketable Parcels Payment Date 23 January 2019

## Important Information

Please note that ITL makes no recommendation as to whether you should sell your Unmarketable Parcel. If you are unsure regarding which option to choose, or if you require further information regarding the financial, legal or tax consequences of participating in the Facility, you should consult your legal, financial or taxation adviser.

Yours Sincerely

Trevor Doolan  
Company Secretary

**Subregister****SRN/HIN.**

## Share Retention Form

**IMPORTANT:** This is an important document and requires your immediate attention. ITL Health Group Limited ('Company') is implementing a sale facility for holders of parcels of the Company's shares valued at less than \$500 ('Sale Facility'). Further details regarding the Sale Facility are set out in the letter to you from the Company dated 5 December 2018, which accompanies this form. If you do not want the parcel of shares in the Company referred to below sold under the Sale Facility, you must complete this form and return it so that it is received by the Company's share registry no later than 5.00pm (AEDT) on 16 January 2019. If you are in any doubt as to how to deal with this form, you should consult your professional adviser. If your holding of the Company's shares increases to more than \$500 by on market purchases or otherwise, then your holding will not be sold under the Sale Facility.

### A Number of shares held as at Record Date

The number of shares that you held at 7pm (AEDT) on 29 November 2018.

### B Retention of shares

☐

I/We refer to the letter from the company dated 5 December 2018 and hereby give notice that we would like to retain my/our shares.

### C Contact details (Enter your contact details below)

CONTACT NAME	TELEPHONE WORK	TELEPHONE HOME	EMAIL ADDRESS
	( )	( )	

### D Shareholder Signature

By signing and returning this form, I/we confirm that I/we understand that my/our shares will **NOT BE SOLD** under the Sale Facility.

Individual or Securityholder 1

Sole Director and Sole Company Secretary

Securityholder 2

Director

Securityholder 3

Director/Company Secretary

Day Month Year

**This form must be received by no later than  
5.00pm (AEDT) on 16 January 2019**

**LODGEMENT INSTRUCTIONS ARE ON THE REVERSE OF THIS FORM**

# Additional information

## How to complete this form

- A. This is the number of shares that you held at 7pm on 29 November 2018.
- B. If you would like to retain your shares, please mark the box on the front of this form and return it to the Company's share registry in accordance with the lodgement instructions below. If this form is not received by 5.00pm (AEDT) on 16 January 2019, and you have not otherwise validly notified the Company that you wish to retain your shares, the Company will be entitled to sell your shares on your behalf. **IF YOU WOULD LIKE THE COMPANY TO SELL YOUR SHARES, YOU SHOULD NOT COMPLETE THIS FORM.**
- C. Enter your **contact details** so we may contact you regarding your form.
- D. The form **must** be signed. In the spaces provided. You must sign this form as follows:

**Individual:** Where the holding is in only one name, this form is to be signed by the securityholder.

**Joint Holding:** Where the holding is in more than one name, all the securityholders must sign.

**Power of Attorney:** To sign under a Power of Attorney, you must have already lodged it with the registry. Alternatively, attach a certified photocopy of the Power of Attorney to this form when you return it.

**Companies:** this form must be signed by a Director jointly with either another Director or a Company Secretary. Where the company has a Sole Director who is also the Sole Company Secretary, this form must be signed by that person. **Please indicate the office held by signing in the appropriate place.**

## Lodgement of this Form

If you wish to retain your shares, this form must be completed and returned to the share registry by no later than 5.00pm (AEDT) on 16 January 2019. If you are returning your form by post, please allow sufficient time for collection and delivery by postal services. The postal rule does not apply, which means that to be valid your completed form must be received by no later than 5.00pm (AEDT) on 16 January 2019.

Mailing address	Delivery address	By Email	By Fax
ITL Health Group Limited C/- Boardroom Pty Limited GPO Box 3993 SYDNEY NSW 2001	ITL Health Group Limited C/- Boardroom Pty Limited Level 12 225 George Street SYDNEY NSW 2000	corporateactions@boardroomlimited.com.au	+61 2 9290 9655

## Consolidation of shareholdings

If you have more than one holding on the Company register, you should consider consolidating them. For further information regarding this, please contact Boardroom Pty Limited on 1300 737 760 (within Australia) or +61 2 9290 9600 (outside Australia).

## Changes of Address Supported by your Signature(s)

If your address is not exactly as shown, please provide details below. This is only relevant for Issuer Sponsored registered holdings. CHESS holders must notify your sponsoring broker for amendments to holdings on the CHESS Subregister.

CHANGE OF ADDRESS DETAILS – ISSUER SPONSORED ONLY		
SIGN HERE FOR ADDRESS AMENDMENTS:		

Shareholder 1 (Individual) / Sole Director & Sole Company Secretary	Joint Shareholder 2 (Individual) / Director	Joint Shareholder 3 (Individual) / Director/Company Secretary (Delete one)
---	--	--

## Privacy Statement

Boardroom Pty Limited advises that Chapter 2C of the *Corporations Act 2001* (Cth) requires information about you as a shareholder (including your name, address and details of the shares you hold) to be included in the public register of the entity in which you hold shares. Information is collected to administer your shareholding and if some or all of the information is not collected then it might not be possible to administer your shareholding. Your personal information may be disclosed to the entity in which you hold shares. You can obtain access to your personal information by contacting us at the address or telephone number shown on the Application Form. Our privacy policy is available on our website <https://www.boardroomlimited.com.au/corp/privacy-policy>